nach oben

Magnetic Resonance Materials in Physics, Biology and Medicine

Erschienen in:

10.12.2019 | Research Article

Stability evaluation of Gd chelates for macromolecular MRI contrast agents

verfasst von: Masayuki Yokoyama, Kouichi Shiraishi

Erschienen in: Magnetic Resonance Materials in Physics, Biology and Medicine | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

We try to establish designs for the macromolecular agents possessing high Gd³⁺-chelating stability, because free Gd³⁺ ion released from Gd chelates is known as a risk factor to cause toxic side effects and a safety concern.

Materials and methods

We prepared three types of Gd-based macromolecular MRI contrast agents from a synthetic polymer (poly(glutamic acid) homopolymer or poly(ethylene glycol)-b-poly(lysine) block copolymer) and a chelating moiety (DO3A or DOTA) having two strategic designs for high chelate stability. Then, we examine the in vitro Gd³⁺-chelate stability of these macromolecular MRI contrast agents.

Results

The prepared macromolecular agents exhibited the same or higher Gd³⁺-chelate stability as/than did Gd-DOTA that possesses the highest Gd³⁺-chelate stability among the approved small-MW Gd-chelate MRI contrast agent.

Discussion

Our macromolecular design was considered to work well for high Gd³⁺-chelate stability.

Nur mit Berechtigung zugänglich

Caravan P, Ellison JJ, McMurry TJ, Lauffer RB (1999) Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 99:2293–2352. https://doi.org/10.1021/cr980440x CrossRefPubMed

Kubíček V, Tóth É (2009) Design and function of metal complexes as contrast agents in MRI. Adv Inorg Chem 61:63–129. https://doi.org/10.1016/S0898-8838(09)00202-5 CrossRef

Aime S, Caravan PJ (2009) Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. Magn Reson Imaging 30:1259–1267. https://doi.org/10.1002/jmri.21969 CrossRef

Tóth É, Helm L, Merbach AE (2009) Metal complexes as MRI contrast enhancement agents. In: McCleverty JA, Meyer J (eds) Comprehensive coordination chemistry II, vol 9. Elsevier Science, Amsterdam, pp 841–881. https://doi.org/10.1016/B0-08-043748-6/09007-1

Pesaresi I, Cosottini M (2010) MR angiography contrast agents. In: Neri R, Cosottini M, Caramella D (eds) MR angiography of the body technique and clinical application. Springer, New York, pp 7–16. https://doi.org/10.1007/978-3-540-79717-3

Tóth É, Helm L, Merbach AE (2015) Metal complexes as MRI contrast enhancement agents. In: Reference module in chemistry, molecular sciences and chemical engineering. Elsevier, Amsterdam. https://doi.org/10.1016/B978-0-12-409547-2.11263-6

Tweedle MF (1992) Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Investig Radiol 27(Suppl 1):S7CrossRef

Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362. https://doi.org/10.1681/ASN.2006060601 CrossRefPubMed

Do C, Barnes JL, Tan C, Wagner B (2014) Type of MRI contrast, tissue gadolinium, and fibrosis. Am J Physiol Renal Physiol 307:F844–855. https://doi.org/10.1152/ajprenal.00379.2014 CrossRefPubMedPubMedCentral

10.

Thomsen HS, Morcos SK, Dawson P (2006) Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 61:905–906. https://doi.org/10.1016/j.crad.2006.09.003 CrossRefPubMed

11.

Thomsen HS (2006) Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16:2619–2621. https://doi.org/10.1007/s00330-006-0495-8 CrossRefPubMedPubMedCentral

12.

Morcos SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80:73–76. https://doi.org/10.1259/bjr/17111243 CrossRefPubMed

13.

Braveman IM, Cowper S (2010) Nephrogenic systemic fibrosis. F1000 Med Rep 2:84. https://doi.org/10.3410/M2-84 CrossRef

14.

Ramalho J, Ramalho M, Jay M, Burke LM, Semelka RC (2016) Gadolinium toxicity and treatment. Magn Reson Imaging 34:1394–1398. https://doi.org/10.1016/j.mri.2016.09.005 CrossRefPubMed

15.

Semelka RC, Ramalho M, AlObaidy M, Ramalho J (2016) Gadolinium in humans: a family of disorders. Am J Roentgenol 207:229–233. https://doi.org/10.2214/AJR.15.15842 CrossRef

16.

Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M (2012) MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 36:1060–1071. https://doi.org/10.1002/jmri.23725 CrossRefPubMed

17.

Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270:834–841. https://doi.org/10.1148/radiol.13131669 CrossRefPubMed

18.

Kanda T, Osawa M, Oba H, Toyoda K, Kotoku J, Haruyama T, Takeshita K, Furui S (2015) High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 275:803–809. https://doi.org/10.1148/radiol.14140364 CrossRefPubMed

19.

Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276:228–232. https://doi.org/10.1148/radiol.2015142690 CrossRefPubMed

20.

Kanda T, Nakai Y, Oba H, Toyoda K, Kitajima K, Furui S (2016) Gadolinium deposition in the brain. Magn Reson Imaging 34:1346–1350. https://doi.org/10.1016/j.mri.2016.08.024 CrossRefPubMed

21.

Tweedle MF, Hagan JJ, Kumar K, Mantha S, Chang CA (1991) Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging 9:409–415CrossRefPubMed

22.

Wedeking P, Kumar K, Tweedle MF (1992) Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 10:641–648CrossRefPubMed

23.

Tweedle MF (2016) Gadolinium deposition: is it chelated or dissociated gadolinium? How can we tell? Magn Reson Imaging 34:1377–1382. https://doi.org/10.1016/j.mri.2016.09.003 CrossRefPubMed

24.

Idée JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20:563–576. https://doi.org/10.1111/j.1472-8206.2006.00447.x CrossRefPubMed

25.

White GW, Gibby WA, Tweedle MF (2006) Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Investig Radiol 41:272–278. https://doi.org/10.1097/01.rli.0000186569.32408.95 CrossRef

26.

Gibby WA, Gibby KA, Gibby WA (2004) Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Investig Radiol 39:138–142CrossRef

27.

Ostrowitzki S, Fick J, Roberts TP, Wendland MF, Aldape KD, Mann JS, Israel MA, Brasch RC (1998) Comparison of gadopentetate dimeglumine and albumin-(Gd-DTPA)30 for microvessel characterization in an intracranial glioma model. J Magn Reson Imaging 8:799–806. https://doi.org/10.1002/jmri.1880080408 CrossRefPubMed

28.

Helbich TH, Gossman A, Mareski PA, Radüchel B, Roberts TP, Shames DM, Mühler M, Turetschek K, Brasch RC (2000) A new polysaccharide macromolecular contrast agent for MR imaging: biodistribution and imaging characteristics. J Magn Reson Imaging 11:694–701. https://doi.org/10.1002/1522-2586(200006)11:6%3c694:AID-JMRI17%3e3.0.CO;2-1 CrossRefPubMed

29.

Granato L, Vander Elst L, Henoumont C, Muller RN, Laurent S (2018) Optimizing water exchange rates and rotational mobility for high-relaxivity of a novel Gd-DO3A derivative complex conjugated to inulin as macromolecular contrast agents for MRI. Chem Biodivers 15:e1700487. https://doi.org/10.1002/cbdv.201700487 CrossRef

30.

Lu ZR, Wang X, Parker DL, Goodrich KC, Buswell HR (2003) Poly(l-glutamic acid) Gd(III)-DOTA conjugate with a degradable spacer for magnetic resonance imaging. Bioconj Chem 14:715–719. https://doi.org/10.1021/bc0340464 CrossRef

31.

Ye F, Ke T, Jeong EK, Wang X, Sun Y, Johnson M, Lu ZR (2003) Noninvasive visualization of in vivo drug delivery of poly(l-glutamic acid) using contrast-enhanced MRI. Mol Pharm 3:507–515. https://doi.org/10.1021/mp060052g CrossRef

32.

Schuhmann-Giampieri G, Schmitt-Willich H, Frenzel T, Press WR, Weinmann HJ (1991) In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging. Investig Radiol 26:969–974CrossRef

33.

Grandin C, Van Beers BE, Demeure R, Goudemant JF, Mottet I, Pringot J (1995) Comparison of gadolinium-DTPA and polylysine-gadolinium-DTPA-enhanced magnetic resonance imaging of hepatocarcinoma in the rat. Investig Radiol 30:572–581CrossRef

34.

Bogdanov A Jr, Wright SC, Marecos EM, Bogdanova A, Martin C, Petherick P, Weissleder R (1997) A long-circulating co-polymer in “passive targeting” to solid tumors. Drug Target 4:321–330. https://doi.org/10.3109/10611869708995848 CrossRef

35.

Bogdanov AA Jr, Weissleder R, Frank W, Bogdanova AV, Nossif N, Schaffer BK, Tsai E, Papisov MI, Brady TJ (1993) A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. Radiology 187:701–706. https://doi.org/10.1148/radiology.187.3.8497616 CrossRefPubMed

36.

Tombach B, Schneider J, Reimer P, Mahler M, Ebert W, Shams K, Heindel W (2006) CMR 2005: 6.05; Phase I clinical trial of gadomer. Contrast Media Mol Imaging 1:69. https://doi.org/10.1002/cmmi.38 CrossRef

37.

Kobayashi H, Kawamoto S, Choyke PL, Sato N, Knopp MV, Star RA, Waldmann TA, Tagaya Y, Brechbiel MW (2003) Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. Magn Reson Med 50:758–766. https://doi.org/10.1002/mrm.10583 CrossRefPubMed

38.

Venditto VJ, Regino CA, Brechbiel MW (2005) PAMAM dendrimer based macromolecules as improved contrast agents. Mol Pharm 2:302–311. https://doi.org/10.1021/mp050019e CrossRefPubMed

39.

Ndiaye M, Malytskyi V, Vangijzegem T, Sauvage F, Wels M, Cadiou C, Moreau J, Henoumont C, Boutry S, Muller RN, Harakat D, Smedt S, Laurent S, Chuburu F (2019) Comparison of MRI properties between multimeric DOTAGA and DO3A Gadolinium-Dendron conjugates. Inorg Chem 58:12798–12808. https://doi.org/10.1021/acs.inorgchem.9b01747 CrossRefPubMed

40.

Ladd DL, Hollister R, Peng X, Wei D, Wu G, Delecki D, Snow RA, Toner JL, Kellar K, Eck J, Desai VC, Raymond G, Kinter LB, Desser TS, Rubin DL (1999) Polymeric gadolinium chelate magnetic resonance imaging contrast agents: design, synthesis, and properties. Bioconj Chem 10:361–370. https://doi.org/10.1021/bc980086+ CrossRef

41.

Ye Z, Zhou Z, Ayat N, Wu X, Jin E, Shi X, Lu ZR (2016) A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent. Contrast Media Mol Imaging 11:32–40. https://doi.org/10.1002/cmmi.1655 CrossRefPubMed

42.

Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392PubMed

43.

Maeda H (2012) Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 164:138–144. https://doi.org/10.1016/j.jconrel.2012.04.038 CrossRefPubMed

44.

Thonon D, Jacques V, Desreux JF (2007) A gadolinium triacetic monoamide DOTA derivative with a methanethiosulfonate anchor group. Relaxivity properties and conjugation with albumin and thiolated particles. Contrast Media Mol Imaging 2:24–34. https://doi.org/10.1002/cmmi.121 CrossRefPubMed

45.

Shiraishi K, Kawano K, Minowa T, Maitani Y, Yokoyama M (2009) Preparation and in vivo imaging of PEG-poly(l-lysine)-based polymeric micelle MRI contrast agents. J Control Release 136:14–20. https://doi.org/10.1016/j.jconrel.2009.01.010 CrossRefPubMed

46.

Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann HJ (2008) Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Investig Radiol 4:817–828. https://doi.org/10.1097/RLI.0b013e3181852171 CrossRef

47.

Ma H, Shiraishi K, Minowa T, Kawano K, Yokoyama M, Hattori Y, Maitani Y (2010) Accelerated blood clearance was not induced for a gadolinium-containing PEG-poly(l-lysine)-based polymeric micelle in mice. Pharm Res 27:296–302. https://doi.org/10.1007/s11095-009-0018-9 CrossRefPubMed

48.

Yokoyama M, Kwon GS, Okano T, Sakurai Y, Seto T, Kataoka K (1992) Preparation of micelle-forming polymer-drug conjugates. Bioconj Chem 3:295–301CrossRef

49.

Duncan R, Kopecková-Rejmanová P, Strohalm J, Hume I, Cable HC, Pohl J, Lloyd JB, Kopecek J (1987) Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. Br J Cancer 55:165–174. https://doi.org/10.1038/bjc.1987.33

Titel: Stability evaluation of Gd chelates for macromolecular MRI contrast agents
verfasst von: Masayuki Yokoyama
Kouichi Shiraishi
Publikationsdatum: 10.12.2019
Verlag: Springer International Publishing
Erschienen in: Magnetic Resonance Materials in Physics, Biology and Medicine / Ausgabe 4/2020
Print ISSN: 0968-5243
Elektronische ISSN: 1352-8661
DOI: https://doi.org/10.1007/s10334-019-00805-8

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Stability evaluation of Gd chelates for macromolecular MRI contrast agents

Abstract

Objective

Materials and methods

Results

Discussion

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Materials and methods

Results

Discussion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Cell density quantification with TurboSPI: R2* mapping with compensation for off-resonance fat modulation

Pilot study utilizing MRI 3D TGSE PASL (arterial spin labeling) differentiating clearance rates of labeled protons in the CNS of patients with early Alzheimer disease from normal subjects

Comparison between synthetic and conventional magnetic resonance imaging in patients with multiple sclerosis and controls

Clinical evaluation of fully automated thigh muscle and adipose tissue segmentation using a U-Net deep learning architecture in context of osteoarthritic knee pain

Performing IVIM-DWI using the multifunctional nanosystem for the evaluation of the antitumor microcirculation changes

Development of a new phantom simulating extracellular space of tumor cell growth and cell edema for diffusion-weighted magnetic resonance imaging

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie